Hypersensitivity and tumor lysis syndrome associated with cetuximab treatment: should we be afraid?

Basit Öğe Kaydı
dc.contributor.authorCihan, Sener
dc.contributor.authorAtasoy, Ajlan
dc.contributor.authorYildirim, Yasar
dc.contributor.authorBabacan, Nalan Akgul
dc.contributor.authorKos, Tugba Fahriye
dc.date.accessioned2024-04-24T17:27:34Z
dc.date.available2024-04-24T17:27:34Z
dc.date.issued2015
dc.departmentDicle Üniversitesien_US
dc.description.abstractThe majority of the chemotherapy agents in use today cause various infusion reactions, from mild flushing to life-threatening events. The frequency of the reported hypersensitivity reactions induced by cetuximab varies between 3% and 22%. It is recommended in the literature to stop the infusion and replace cetuximab with panitumumab in case of hypersensitivity reactions observed during the treatment of colon cancer. Tumor lysis syndrome (TLS) may occur in colorectal cancers with heavy tumor load. Tumor lysis syndrome may be life-threatening. In our patient with widespread bone and liver metastases, treatment continued with cetuximab as a combination therapy with irinotecan in spite of the hypersensitivity and TLS led to a complete treatment response. The complete response observed after 3 months through continued therapy in our patient may present an example supporting treatment with cetuximab in spite of severe reactions.en_US
dc.identifier.doi10.5301/tj.5000246
dc.identifier.endpageE45en_US
dc.identifier.issn0300-8916
dc.identifier.issn2038-2529
dc.identifier.issue2en_US
dc.identifier.pmid25721679
dc.identifier.scopus2-s2.0-84930578964
dc.identifier.scopusqualityQ3
dc.identifier.startpageE40en_US
dc.identifier.urihttps://doi.org/10.5301/tj.5000246
dc.identifier.urihttps://hdl.handle.net/11468/20060
dc.identifier.volume101en_US
dc.identifier.wosWOS:000358316400002
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherSage Publications Ltden_US
dc.relation.ispartofTumori Journal
dc.relation.publicationcategoryDiğeren_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCetuximaben_US
dc.subjectComplete Responseen_US
dc.subjectHypersensitivityen_US
dc.subjectTumor Lysis Syndromeen_US
dc.titleHypersensitivity and tumor lysis syndrome associated with cetuximab treatment: should we be afraid?en_US
dc.titleHypersensitivity and tumor lysis syndrome associated with cetuximab treatment: should we be afraid?
dc.typeEditorialen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu